Clinical Challenges
Central nervous system (CNS) infections, dominated by meningitis and encephalitis, are life-threatening acute conditions associated with high mortality and permanent neurological disability. For tertiary hospital inpatient and critical care settings, conventional diagnostic approaches face four core unmet needs:
Complex, heterogeneous pathogen spectrum with poor differential diagnostic yield
Meningitis can be caused by bacteria, viruses and fungi, with distinct pathogen profiles across neonatal, adult and immunocompromised populations. Conventional Gram staining and culture methods have extremely limited coverage, with low sensitivity for viral and fungal pathogens. Mixed infections are frequently missed, leaving clinicians unable to rapidly distinguish infection etiology and guide targeted therapy.
Long turnaround time misses the golden treatment window
Acute bacterial meningitis requires targeted antimicrobial intervention within hours of onset to reduce mortality and sequelae. Traditional cerebrospinal fluid (CSF) culture takes 24–72 hours to deliver results, while viral and fungal testing often requires external laboratory referral. Clinicians are forced to rely on empiric broad-spectrum therapy, driving antimicrobial resistance and worsening patient prognosis.
Invasive, low-volume samples with high diagnostic access barriers
CSF collection is an invasive procedure that yields limited sample volume. Conventional workflows require sample splitting for multiple separate tests and rely entirely on centralized PCR laboratories. Lengthy sample transfer and batch testing cycles extend total turnaround time (TAT), making rapid on-site diagnosis infeasible for neurology wards, ICUs and pediatric departments.
Insufficient detection capacity for high-risk special populations
Routine panels frequently overlook pathogens specific to neonatal meningitis and immunocompromised hosts (e.g., transplant recipients, oncology patients) such as Listeria monocytogenes, Cryptococcus species and cytomegalovirus, resulting in high missed diagnosis rates and poor clinical outcomes for vulnerable groups.
Core Clinical Benefits
The Meningitis Pathogen Nucleic Acid Detection Kit, paired with the Multi-Disc fully automated nucleic acid analysis platform, directly addresses the above critical care pain points:
One-stop comprehensive 18-plex etiological profiling
The kit covers 18 CE-marked pathogens spanning bacteria, viruses and fungi, with an additional Cytomegalovirus (CMV) target available for research use only (RUO). It fully covers common pathogens responsible for community-acquired, hospital-acquired and neonatal meningitis. A single run distinguishes bacterial, viral and fungal infections as well as mixed infections, drastically reducing missed diagnosis rates and eliminating the need for sequential separate testing.
Rapid around 80 minute results to improve critical care outcomes
Total testing time is only around 80 minutes, with just 1 minute of hands-on sample loading — far faster than culture-based methods. Rapid etiological results enable clinicians to promptly adjust empiric regimens, initiate targeted antimicrobial/antiviral therapy within the golden treatment window, reduce mortality and neurological sequelae, and shorten hospital length of stay.
Ward-level decentralized testing with shortened diagnostic TAT
The fully automated closed system requires no standardized PCR laboratory or specialized molecular technicians, and can be deployed directly in neurology, neurosurgical ICU, pediatrics and infectious disease departments. CSF samples can be tested on demand, eliminating transport-related sample degradation and significantly compressing overall diagnostic turnaround time for critically ill patients.
Optimized coverage for high-risk patient populations
The panel includes core pathogens for neonatal meningitis (Streptococcus agalactiae, Escherichia coli K1, Listeria monocytogenes) and key pathogens for immunocompromised patients (Cryptococcus neoformans/gattii, CMV), improving diagnostic yield for difficult and high-risk cases and supporting precision care for vulnerable populations.
Core Product Advantages
Severe-care oriented panel design tailored for CNS infections
The 18-plex panel is purpose-built for inpatient severe meningitis scenarios, covering all high-prevalence bacterial, viral and fungal CNS pathogens. It meets the diagnostic needs of adult, pediatric and neonatal patients as well as immunocompromised populations, with the additional RUO CMV target supporting clinical research applications.
Fully automated closed sample-to-result workflow
Powered by proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true "load-and-go" detection ideal for precious low-volume CSF samples.

Balanced throughput for diverse inpatient scenarios
Compatible with the Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer, the platform supports parallel testing of 4 CSF samples per run with full results available in around 80 minutes. It balances speed and batch processing capacity to support emergency stat testing, routine inpatient diagnosis and nosocomial infection screening.
Lyophilized reagents for room-temperature storage and transport
With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance and greatly reducing storage and distribution costs for facilities of all sizes.
Zero cross-contamination closed cartridge system
Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces laboratory quality control burden, and ensures accurate, reliable results for limited-volume CSF samples.
CE-compliant with validated CSF sample compatibility
Validated for human cerebrospinal fluid (CSF) samples. All 18 core targets are CE-marked, with Cytomegalovirus designated for research use only (RUO), meeting regulatory requirements for clinical meningitis diagnosis across global markets.